RxDoctor Payments Data

Joseph Aiello, MD

Nephrology · Asheville, NCNPI 1942203310

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $267 of the $383 with a category attached, or 69.6%. 5 manufacturers reported payments, led by Medtronic at 39.4% of the total. 2025 is the largest year on record at $269, 3.0 times the $90 reported in 2019. That places this record below the midpoint for nephrology clinicians in NC, where the typical reported total is $1,119.

$383in general payments, 2019–2025

Across 7 payments — averaging $54.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$151
  • Abbott$116
  • Mallinckrodt Enterprises LLC$90
  • Amgen$20
  • Travere Therapeutics, Inc.$7
$631,089in research payments, 2019–2025

Across 95 payments — averaging $6643.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$295K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$177K
  • Gilead$116K
  • GSK$23K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
  • Vertex$6K
  • plus $2K from 1 others

What the payments were for

  • Food & beverage$26770%
  • Education$11730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$383 in reported general payments places this provider in the 30th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$201,318
Medicare patients
581
Services billed
1,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$27,759
FarxigaDapagliflozin Propanediol27$22,708
EliquisApixaban16$18,086
Sevelamer Carbonate25$3,261
Bumetanide66$2,968
Telmisartan90$1,922
Chlorthalidone173$1,523
Amlodipine Besylate154$1,171
Losartan Potassium91$879
Spironolactone100$577
Calcitriol39$562
Metoprolol Succinate19$557
Olmesartan Medoxomil16$517
Carvedilol37$435
Atorvastatin Calcium44$424

Paid to pharmacies, not to this prescriber.

Other nephrology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →